A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

Clinical trial NCT03883100 · UNKNOWN

Trial details

NCT number: NCT03883100
Sponsor: Ascentage Pharma Group Inc.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Myeloid Leukemia - Accelerated Phase

Start date: 2019-04-08
Primary completion: 2024-04-01
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.